Comparative evaluation of glutamate-sensitive radiopharmaceuticals: Technetium-99m-glutamic acid and technetium-99m-diethylenetriaminepentaacetic acid-bis(glutamate) conjugate for tumor imaging

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 6, 2010, Pages 645-655

  Kakkar, Dipti ^a,b   Tiwari, Anjani K ^a   Chuttani, Krishna ^a   Kaul, Ankur ^a   Singh, Harpal ^b   Mishra, Anil K ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

Gamma scintigraphy; glutamic acid; radiopharmaceuticals; technetium

Indexed keywords

CHELATING AGENT; DIETHYLENETRIAMINEPENTAACETIC ACID BIS(GLUTAMIC ACID) CONJUGATE TC 99M; GLUTAMIC ACID; GLUTAMIC ACID TC 99M; LIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BIOACCUMULATION; BIOLOGICAL ACTIVITY; BLOOD; BONE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STABILITY; DRUG TISSUE LEVEL; EXPERIMENTAL NEOPLASM; GAMMA SCINTIGRAPHY; HEART; IN VIVO STUDY; INFRARED SPECTROSCOPY; INTESTINE; ISOTOPE LABELING; KIDNEY; LIPOPHILICITY; LIVER; LUNG; MASS SPECTROMETRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RADIOCOMPLEXATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; STOMACH; TUMOR SCINTISCANNING; WHOLE BODY IMAGING;

ANIMAL STRUCTURES; ANIMALS; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE; DRUG STABILITY; GLUTAMIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NEOPLASMS; PENTETIC ACID; RABBITS; RADIOPHARMACEUTICALS; TECHNETIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING;

EID: 78651291613     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0848     Document Type: Article

References (31)

1. Signore A et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001;28:1555.
2. Dinkelborg LM et al. Molecular imaging of atherosclerosis using a technetium-99m-labelled endothelin derivative. J Nucl Med 1998;10:1819.
3. Edwards DS et al. RP463: a stabilized technetium-99m complex of a hydrazine nicotinamide derivatives chemo-tactic peptide for infection imaging. Bioconj Chem 1999; 10:884.
4. Welling MM et al. Technitium-99m labeled antimicrobial peptides discriminate between bacterial infections and ster-ile inflammations. Eur J Nucl Med 2000;27:292.
5. 99mTc-labeled human neutrophil peptide-1. J Nucl Med 1999;40:2073.
6. 99mTc labeled metronidazole. Pharm Res 1999;16:743.
7. 99mTc-DTPA-mannosyl-dextran. J Nucl Med 2001; 42:951.
8. Johnstone RM, Scholefield PG. Amino acids transport in tumor cells. Cancer Res 1965;9:143.
9. Souba WW, Pacitti AJ. How amino acids get into cells: mechanisms, models, menus and mediators. J Parenter Enteral Nutr 1992;16:569.
10. 11C-L-Methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008;10:1.
11. 11C]-l- methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868.
12. Landel AM, Hammond WG, Meguid MM. Aspects of amino acid and protein metabolism in cancer-bearing states. Cancer 1985;55:230.
13. Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: A potential tumor-detecting agent. J Nucl Med 1998;39:663.
14. Kubota K, Ishiwata K, Kubota R, et al. Feasibility of fluorine-18-fluorophenylalanine for tumor imaging compared with carbon-11-L-methionine. J Nucl Med 1996;37:320.
15. Medina MA, Quesada AR, Núnezde Castro I. L-Glutamine transport in native vesicles isolated from Ehrlich ascites tu-mor cell membranes. J Bioenerg Biomembr 1991;23:689.
16. Medina MA, Sánchez-Jiménez F, Márquez J, et al. Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem 1992;113:1.
17. Souba WW. Glutamine and cancer. Ann Surg 1993;218:715.
18. Klimberg VS, McClellan JL. Glutamine, cancer, and its therapy. Am J Surg 1996;172:418.
19. Carrascosa JM, Martínez P, Núnezde Castro I. Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells. Cancer Res 1984;44:3831.
20. Quesada AR, Medina MA, Márquez J, et al. Contribution by host tissues to circulating glutamine in mice inoculated with Ehrlich ascites tumor cells. Cancer Res 1988;48:1551.
21. 99mTc-DTPA-Amino Acids conjugate as specific SPECT pharmaceuticals for tu-mour imaging. Chem Biol Drug Des 2009;74:159.
22. Liu S, Edwards DS. Synthesis and characterization of two (111)In-labeled DTPA-peptide conjugates. Bioconjug Chem 2001;12:630.
23. Fu Y et al. Synthesis of a sialyl lewis mimetic conjugated with DTPA, potential ligand of new contrast agents for medical imaging. Eur J Org Chem 2002;2002:3966.
24. Laurent S et al. Bis(phenylethylamide) derivatives of Gd-DTPA as potential receptor-specific MRI contrast agents. Eur J Inorg Chem 2007;2007:2061.
25. Fritzberg AR, Klingensmith WC III. Quest for the perfect hepatobiliary radiopharmaceutical. J Nucl Med 1982;23:543.
26. D-Phe l-octreotide. Eur J Nucl Med 2000;27:1580.
27. D-Phe l-octreotide. Eur J Nucl Med 2000;27:628.
28. 99mTc-DTPA-bis(methionine). Bioconjug Chem 2010;21:229.
29. Anelli PL, Fedeli F, Gazzotti O, et al. L-glutamic acid and L-lysine as useful building blocks for the preparation of bifunctional DTPA-like ligands. Bioconjug Chem 1999; 10:137.
30. 99mTc-DTPA-DG] as a potential im-aging modality for tumours. Appl Rad Isot 2006;64:342.
31. 99mTc-DTPA-bis(His) as a potential probe for tumor imaging with SPECT. Can Biother Radiopharm 2009;24:615.